Paris-based pharmaceutical technology company Aqemia has secured 30 million euros ($29.5 million) in its Series A funding round.
Eurazeo, a private equity company, and Bpifrance spearheaded the round with participation from Elaia.
Aqemia will allocate the proceeds towards growing its drug discovery and its proprietary therapeutic assets pipeline.
In 2019, the company had completed $985,785 in its pre-seed investment round from Elaia